CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-beta-producing NK cells that stabilize Tregs for long-term therapeutic efficacy in immune-mediated disorders

Horwitz DA, Kim D, Kang C, Brion K, Bickerton S, La Cava A. CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-β-producing NK cells that stabilize Tregs for long-term therapeutic efficacy in immune-mediated disorders. Front Immunol. 2025 Jul 29;16:1587237. doi: 10.3389/fimmu.2025.1587237. PMID: 40799646; PMCID: PMC12339487.


Related Posts